Title of Invention	A NOVEL COMPOUND OF THE PRESENT INVENTION
Abstract	A compound represented by the structural formula or a pharmaceutically acceptable salt or solvate thereof.

Full Text

(1-4-PIPERIDINYLJBENZIMIDAZOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS FIELD OF THE INVENTION The present invention relates to novel substituted benzimidazoles and aza- and diaza-derivatives thereof useful as histamine H3 antagonists. The invention also relates to pharmaceutical compositions comprising said compounds and their use in treating inflammatory diseases, allergic conditions and central nervous system disorders. The invention also relates to the use of a combination of novel histamine H3 antagonists of this invention with histamine H1compounds for the treatment of inflammatory diseases and allergic conditions, as well as pharmaceutical compositions comprising a combination of one or more novel histamine H3 antagonist compounds of the invention with one or more histamine H1compounds. BACKGROUND OF THE INVENTION The histamine receptors, H1, H2 and H3 are well-identified forms. The H1 receptors are those that mediate the response antagonized by conventional antihistamines. H1receptors are present, for example, in the ileum, the skin, and the bronchial smooth muscle of humans and other mammals. Through H2 receptor-mediated responses, histamine stimulates gastric acid secretion in mammals and the chronotropic effect in isolated mammalian atria. H3 receptor sites are found on sympathetic nerves, where they modulate sympathetic neurotransmission and attenuate a variety of end organ responses under control of the sympathetic nervous system. Specifically, H3 receptor activation by histamine attenuates norepinephrine outflow to resistance and capacitance vessels, causing vasodilation. Imidazole H3 receptor antagonists are well known in the art. More recently, non-imidazole H3 receptor antagonists have been disclosed in PCT US01/32151, filed October 15, 2001, and US Provisional Application 60/275,417, filed March 13, 2001. US 5,869,479 discloses compositions for the treatment of the symptoms of allergic rhinitis using a combination of at least one histamine H1receptor antagonist and at least one histamine H3 receptor antagonist. SUMMARY OF THE INVENTION The present invention provides novel compounds of formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; a is 0 to 2; b is 0 to 2; n is 1,2 or 3; p is 1, 2 or 3; ris 0, 1,2, or 3; with the provisos that when M2 is N, p is not 1; and that when r is 0, M2 is C(R3); and that the sum of p and r is 1 to 4; M1 is C(R3) or N; M2 is C(R3) or N; X is a bond or C1-C6 alkylene; Y is -C(O)-, -C(S)-, -(CH2)q -, -NR4C(O) -C(0)NR4-, -C(0)CHr, -SO2-, -N(R4)-, -NH-C(=N-CN)- or -C(=N-CN)-NH-; with the provisos that when M1 is N, Y is not -NR4C(0)- or -NH-C(=N-CN}-; when M2 is N, Y is not -C(0)NR4- or -C(=N-CN)-NH-; and when Y is -N(R4)-, M1 is CH and M2 is C(R3); q is 1 to 5, provided that when both M1 and M2 are N, q is 2 to 5; Z is a bond, CrC6 alkylene, CrC6 alkenylene, -C(O)-, -CH(CN)-, -S02- or -CH2C(0)NR4-; k2is0, 1 or 2; R is H, C1-C6 alkyl, halo(CrC5)alkyl-, CrC5 alkoxy, (CrC6)alkoxy- (CrC6)alkyl-,(C1-C6)-alkoxy-(C1-C6)alkoxy, (C1-C6)alkoxy-(CrC6)alkyl-SOo-2, R32-aryl(CrC6)alkoxy-, Rly-aryKd-CeJalkyl-, R32-aryl, R32-aryloxy, R32-heteroaryl, (C3-C6)cycloalkyl, (C3-C6)cyc!oalkyl-(C1-C6)alkyl, (C3-C6)cycloalkyl-(CrC6)alkoxy, (C3-C6)cyC1oalkyl-oxy-, R37-heterocycloalkyl, R37-heterocycloalkyl-oxy-, R37-heterocycloalkyl-(C1-C6)alkoxy, N(R30)(R31)-(CrC6)alkyl-,>N(R30)(R31), -NH-(C1-C6)alkyl-0-(C1-C6)alky!, -NHC(0)NH(R29); R29-S(0)o-2-, halo(CrC6)alkyl«S(0)o-2-, N(R3°)(R31MCrC6)alkyl-S(0)o-2- or benzoyl; R8 is H, C1-C6 alkyl, halo(C1-C6)alkyl-, (CrC6)alkoxy-(C1-C6)alkyl-, R32-aryl(d-C6)alkyl-, R32-aryl, R32-heteroaryl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(CrC6)alkyl, R37-heterocycloalkyl, N(R30)(R31)-(C1-C6)alkyl-. R29-S(0)2-, halo(C1-C6)alkyl-S(0)2-, R29-S(0)o.r(C2-C6)alkyl->halo(CrC6)alkyl-S(0)o-1-(C2-C6)alkyl-; R2 is a six-membered heteroaryl ring having 1 or 2 heteroatoms independently selected from N or N-O, with the remaining ring atoms being carbon; a five-membered heteroaryl ring having 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, with the remaining ring atoms being carbon; R32-quinolyl; R32-aryl; heterocycloalkyl; (C3-C6)cycloalkyl; C1C6 alkyl; hydrogen; thianaphthenyl; wherein said six-membered heteroaryl ring or said five-membered hete optionally substituted by R6; R3 is H, halogen, C1C6 alkyl, -OH. (d-CeJalkoxy or -NHS02-(C1C6)alkyl; R4 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, R33-aryl, R33-aryl(C1C6)alkyl, and R32-heteroaryl; R5 is hydrogen, C1-C6 alkyl, -C(0)R20, -C(0)2R20, -C(O)N(R20)2, (d-CeJalkyl-S02-, or (C1C6)alkyl-S02-NH-; or R4 and R5, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring; R6 is 1 to 3 substituents independently selected from the group consisting of -OH, halogen, C1-Cs alkyl-, C1-C6 alkoxy, C1-C6 alkylthio, -CF3, -NR4R5, -CH2-NR4R5, -NHS02R22, -N(S02R22)2f phenyl, R33-phenyl, N02, -C02R4, -CON(R4)2, R12 is independently selected from the group consisting of C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, or fluoro, provided that when R12 is hydroxy or fluoro, then R12 is not bound to a carbon adjacent to a nitrogen; or two R12 substituents form a C1 to C2 alkyl bridge from one ring carbon to another non-adjacent ring carbon; or R12 is =0; R13 is independently selected from the group consisting of C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, or fluoro, provided that when R13 is hydroxy or fluoro then R13 is not bound to a carbon adjacent to a nitrogen; or two R13 substituents fornrj a C1 to C2 alkyl bridge from one ring carbon to another non-adjacent ring carbon; or R13 is =0; R20 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, or aryl, wherein said aryl group is optionally substituted with from 1 to 3 groups independently selected from halogen, -CF3, -OCF3, hydroxyl, or methoxy; or when two R20 groups are present, said two R20 groups taken together with the nitrogen to which they are bound can form a five or six membered heterocyclic ring; R22 is C1-C6 alkyl, R34-aryl or heterocycloalkyl; R24 is H, d-C6 alkyl, -S02R22 or Rly-aryl; R25 is independently selected from the group consisting of C1-C6 alkyl, halogen, -CN, -N02, -CF3, -OH, C1C6 alkoxy, (C1-C6)alkyl-C(0)-t aryl-C(O)-, -C(0)OR29, -N(R4)(R5), N(R4)(R5)-C(0)-, N(R4)(R5)-S(0)1.2-, R22-S(O)0.2-, halo-(d-C6)alkyl- or halo-(C1-C6)alkoxy-(C1-C6)alkyl-; R29 is H, C1C6 alkyl, C3-C6 cycloalkyl, R35-aryl or R35-aryl(C1-C6)alkyl-; R30 is H, C1-C6 alkyl-, R35-aryl or R35-aryl(C1-C6)alkyl-; R31 is H, C1-C6 alkyl-, R35-aryl, R35-aryl(C1-C6)alkyl-, R35-heteroaryl, (d-C6)alkyl-C(0)-r R35-aryl-C(0)-, N(R4)(R5)-C(0)-, (C1-C6)alkyl-S(0)2- or R35-aryl-S(0)2-; or R30 and R31 together are -(CH2)4-5-, -(CH2)2-0-(CH2)2- or -(CH2)2-N(R38)-(CH2)2- and form a ring with the nitrogen to which they are attached; R32 is 1 to 3 substituents independently selected from the group consisting of H, -OH, halogen, C1-C6 alkyl, C1C6 alkoxy, R35-aryl-0-, -SR22, -CF3, -OCF3, -OCHF2, -NR39R40, phenyl, R33-phenyl, N02. -C02R39, -CON(R39)2l -S(0)2R22, -S(O)2N{R20)2t -N(R24)S(0)2R22, -CN, hydroxy-(C1-C6)alkyl-, -OCH2CH2OR22, and R35-aryl(C1-C6)alkyl-0-, or two R32 groups on adjacent carbon atoms together form a -OCH20- or -0(CH2)20- group; R33 is 1 to 3 substituents independently selected from the group consisting of d-C6 alkyl. halogen, -CN, -N02, -CF3, -OCF3, -OCHF2 and -0-(C1C6)alkyl; R34 is 1 to 3 substituents independently selected from the group consisting of H, halogen, -CF3, -OCF3, -OH and -OCH3; R35 is 1 to 3 substituents independently selected from hydrogen, halo, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, phenoxy, -CF3, -N(R36)2, -COOR20 and -N02; R36 is independently selected form the group consisting of H and C1-C6 alkyl; R37 is 1 to 3 substituents independently selected from hydrogen, halo, d-C6 alkyl, hydroxy, d-C6 alkoxy, phenoxy, -CF3, -N(R36)2, -COOR20, -C(0)N(R29)2 and -NO2, or R37 is one or two =0 groups; R38 is H, C1C6 alkyl, R35-aryl, R35-aryl(d-C6)alkyl-, (C1-C6)alkyl-S02 or halo(C1C6)alkyl-S02-; R39 is independently selected from the group consisting of hydrogen, C1-C6 alky!, C3-C6 cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, R33-aryl, R33~aryl(C1-C6)alkyl, and R32-heteroaryl; and R40 is hydrogen, C1-C6 alkyl, -C(0)R20, -C(0)2R2°, -C(O)N(R20)2, (C1-C6)alkyl-SOr, or (C1-C6)alkyl-S02-NH-; or R39 and R40, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring; This invention also provides a pharmaceutical composition comprising an effective amount of compound of at least one compound of formula I and a pharmaceutically acceptable carrier. This invention further provides a method of treating: allergy, allergy-induced airway (e.g., upper airway) responses, congestion (e.g., nasal congestion), hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and aC1dic seC1etion of the gastro-intestinal tract, obesity, sleeping disorders (e.g., hypersomnia, somnolence, and narcolepsy), disturbances of the central nervous system, attention defiC1t hyperactivity disorder (ADHD), hypo and hyperactivity of the central nervous system (for example, agitation and depression), and/or other CNS disorders (such as Alzheimer's, schizophrenia, and migraine) comprising administering to a patient in need of such treatment (e.g., a mammal, such as a human being) an effective amount of at least one compound of formula I. Compounds of this invention are particularly useful for treating allergy, allergy-induced airway responses and/or congestion. This invention further provides a pharmaceutical composition comprising an effective amount of a combination of at least one compound of formula I and at least one H1receptor antagonist in combination with a pharmaceutically acceptable carrier. This invention further provides a method of treating allergy, allergy-induced airway (e.g., upper airway) responses, and/or congestion (e.g., nasal congestion) comprising administering to a patient in need of such treatment (e.g., a mammal, such as a human being) an effective amount of a combination of at least one compound of formula I and at least one H1receptor antagonist. Kits comprising a compound of formula I in a pharmaceutical composition, and a separate H1receptor antagonist in a pharmaceutical compositions in a single package are also contemplated. DETAILED DESC1IPTION OF THE INVENTION Preferred definitions of the variables in the structure of formula I are as follows: R1 is preferably optionally substituted benzimidazolyl or 7-azabenzimidazolyl, wherein R is preferably alkyl, alkoxy, alkoxyalkoxy, alkylthio, heteroaryl or R32-aryl. More preferably, R is -CH3, -CH2CH3, -OCH3, -OCH2CH3v -OCH2CH2CH3, -OCH((CH3)2, -SCH3l -SCH2CH3, pyridyl (espeC1ally 2-pyridyl), pyrimidyt, pyrazinyl, furanyl, oxazolyl or R32-phenyl. R25 is preferably halogen or -CF3 and k is 0 or 1. R2 is preferably a six-membered heteroaryl ring, optionally substituted with one substituent. More preferably, R2 is pyrimidyl, R6-pyrimidyl, pyridyl, R6-pyridyl or pyridazinyl, wherein R6 is -NR4R5, wherein R4and R5 are independently selected from the group consisting of H and (C1-C6)alkylv or R4and R5 together with the nitrogen to which they are attached form a pyrrolidinyl, piperidinyl or morpholinyl ring. More preferably, R6 is -NH2. X is preferably a bond. Y is preferably -C(O)-. Z is preferably straight or branched C1-C3 alkyl. M1 is preferably N; a is preferably 0; and n is preferably 2; the optional double bond is preferably not present (i.e., a single bond is present). M2 is preferably C(R3) wherein R3 is hydrogen or fluorine; b is preferably 0; r is preferably 1; and p is preferably 2. As used herein, the following terms have the following meanings, unless indicated otherwise: alkyl (including, for example, the alkyl portions of arylalkyl and alkoxy) represents straight and branched carbon chains and contains from one to six carbon atoms; alkylene represents a divalent straight or branched alkyl chain, e.g., ethylene (-CH2CH2-) or propylene (-CH2CH2CH2-); Haloalkyl and haloalkoxy represent alkyl or alkoxy chains wherein one or more hydrogen atoms are replaced by halogen atoms, e.g., -CF3, CF3CH2CH2-, CF3CF2~ or CF3S; aryl (including the aryl portion of arylalkyl) represents a carbocyclic group containing from 6 to 14 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl or naphthyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment; arylalkyl represents an aryl group, as defined above, bound to an alkyl group, as defined above, wherein said alkyl group is bound to the compound; cycloalkyl represents saturated carbocyclic rings of from 3 to 6 carbon atoms; halogen (halo) represents fluoro, chloro, bromo and iodo; heteroaryl represents cyclic groups, having 1 to 4 heteroatoms selected from O, S or N, said heteroatom interrupting a carbocyclic ring structure and having a suffiC1ent number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic groups preferably containing from 2 to 14 carbon atoms; examples include but are not limited to isothiazolyl, isoxazolyl, oxazolyl, furazanyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, isothiadiazolyl, thienyl, furanyl (furyl), pyrrolyl, pyrazolyl, pyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyridyl N-oxide (e.g., 2-, 3-, or4-pyridyl N-oxide), triazinyl, pteridinyl, indolyl (benzopyrrolyl), pyridopyrazinyl, isoqinolinyl, quinolinyl, naphthyridinyl; the 5- and 6-membered heteroaryl groups included in the definition of R2 are exemplified by the heteroaryl groups listed above; all available substitutable carbon and nitrogen atoms can be substituted as defined; heterocycloalkyl represents a saturated, carbocylic ring containing from 3 to 15 carbon atoms, preferably from 4 to 6 carbon atoms; examples include but are not limited to 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 2-, 3- or 4-piperidinyl, 2-or 3-pyrrolidinyl, 2- or 3-piperazinyl, 2- or 4-dioxanyl, 1,3-dioxolanyl, 1,3,5-trithianyl, pentamethylene sulfide, perhydroisoquinolinyl, decahydroquinolinyl, trimethylene oxide, azetidinyl, 1-azacycloheptanyl, 1,3-dithianyl, 1,3,5-trioxanyl, morpholinyl, thiomorpholinyl, 1,4-thioxanyl, and 1,3,5-hexahydrotriazinyl.thiazolidinyl, tetrahydropyranyl. In the definition of R32, when two R32 groups on adjacent carbon atoms of an aryl or heteroaryl ring are said to be taken together form a -OCH2O- or-0(CH2)20-group, this means that the two R32 groups form a methylenedioxy or ethylenedioxy ring fused to the aryl or heteroaryl ring. When R12, R13 or R37 is said to be one or two =0 groups, this means that two hydrogen atoms on the same carbon atom of the ring can be replaced by =0; two such groups can be present on a ring. (N) , for example in the structure represents a nitrogen atom that is located at one of the 4 non-fused positions of the ring, i.e., positions 4, 5, 6 or 7 indicated below: Similarly, ly-ly means that two nitrogens are located at any two of the 4 non-fused positions of the ring, e.g., the 4 and 6 positions, the 4 and 7 positions, or the 5 and 6 positions. Also, as used herein, "upper airway" usually means the upper respiratory system-i.e., the nose, throat, and assoC1ated structures. Also, as used herein, "effective amount" generally means a therapeutically effective amount. "Patient" means a mammal, typically a human, although veterinary use is also contemplated. Lines drawn into the rings indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms. Certain compounds of the invention may exist in different isomeric (e.g., enantiomeric, diastereoisomeric and geometric) forms. The invention contemplates all such isomers both in pure form and in admixture, including racemic mixtures. Enol forms and tautomers are also included. The compounds of this invention are ligands for the histamine H3 receptor. The compounds of this invention can also be desC1ibed as antagonists of the H3 receptor, or as H3 antagonists. The compounds of the invention are basic and form pharmaceutically acceptable salts with organic and inorganic aC1ds. Examples of suitable aC1ds for such salt formation are hydrochloric, sulfuric, phosphoric, acetic, C1tric, oxalic, malonic, salicylic, malic, fumaric, sucC1nic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic aC1ds well known to those skilled in the art. The salts are prepared by contacting the free base form with a suffiC1ent amount of the desired aC1d to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium hydroxide, potassium carbonate, ammonia and sodium bicarbonate. The free base forms differ from their corresponding salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the salts are otherwise equivalent to their corresponding free base forms for purposes of this invention. Depending upon the substituents on the inventive compounds, one may be able to form salts with bases. ThusP for example, if there are carboxylic aC1d substituents in the molecule, salts may be formed with inorganic as well as organic bases such as, for example, NaOH, KOH, NH4OH, tetraalkylammonium hydroxide, and the like. The compounds of formula I can exist in unsolvated as well as solvated forms, including hydrated forms, e.g., hemi-hydrate. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol and the like are equivalent to the unsolvated forms for purposes of the invention. The compounds of this invention can be combined with an H1receptor antagonist (i.e., the compounds of this invention can be combined with an H1receptor antagonist in a pharmaceutical composition, or the compounds of this invention can be administered with H1receptor antagonist). Numerous chemical substances are known to have histamine H1receptor antagonist activity and can therefore be used in the methods of this invention. Many H1receptor antagonists useful in the methods of this invention can be classified as ethanolamines, ethylenediamines, alkylamines, phenothiazines or piperidines. Representative H1receptor antagonists include, without limitation: astemizole, azatadine, azelastine, aC1ivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine and triprolidine. Other compounds can readily be evaluated to determine activity at H-t receptors by known methods, including speC1fic blockade of the contractile response to histamine of isolated guinea pig ileum. See for example, WO98/06394 published February 19,1998. Those skilled in the art will appreC1ate that the H1 receptor antagonist is used at its known therapeutically effective dose, or the H1 receptor antagonist is used at its normally presC1ibed dosage. Preferably, said H1receptor antagonist is selected from: astemizole, azatadine, azelastine, aC1ivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine ortriprolidine. More preferably, said H1receptor antagonist is selected from: astemizole, azatadine, azelastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, carebastine, descarboethoxyloratadine, diphenhydramine, doxylamine, ebastine, fexofenadine, loratadine, levocabastine, mizolastine, norastemizole, or terfenadine. Most preferably, said H1receptor antagonist is selected from: azatadine, brompheniramine, cetirizine, chlorpheniramine, carebastine, descarboethoxyloratadine, diphenhydramine, ebastine, fexofenadine, loratadine, or norastemizole. Even more preferably, said Ht antagonist is selected from loratadine, descarboethoxyloratadine, fexofenadine or cetirizine. Still even more preferably, said H1antagonist is loratadine or descarboethoxyloratadine. In one preferred embodiment, said H1receptor antagonist is loratadine. In another preferred embodiment, said H1receptor antagonist is descarboethoxyloratadine. In still another preferred embodiment, said H1receptor antagonist is fexofenadine. In yet another preferred embodiment, said H1receptor antagonist is cetirizine. Preferably, in the above methods, allergy-induced airway responses are treated. Also, preferably, in the above methods, allergy is treated. Also, preferably, in the above methods, nasal congestion is treated. In the methods of this invention wherein a combination of an H3 antagonist of this invention (compound of formula I) is administered with a H1antagonist, the antagonists can be administered simultaneously or sequentially (first one and then the other over a period of time). In general, when the antagonists are administered sequentially, the H3 antagonist of this invention (compound of formula I) is administered first. Compounds of the present invention can be prepared by a number of ways evident to one skilled in the art. Preferred methods include, but are not limited to, the general synthetic procedures desC1ibed herein. One skilled in the art will recognize that one route will be optimal depending on the choice of appendage substituents. Additionally, one skilled in the art will recognize that in some cases the order of steps has to be controlled to avoid functional group incompatibilities. The starting material and reagents used in preparing compounds desC1ibed are either available from commerC1al suppliers such as Aldrich Chemical Co. (Wisconsin, USA) and AC1os Organics Co. (New Jersey, USA) or were prepared by literature methods known to those skilled in the art. One skilled in the art will recognize that the synthesis of compounds of formula I may require the construction of carbon-nitrogen bond. Methods include but are not limited to the use of a substituted aromatic compound or heteroaromatic compound and amine at 0 °C to 200 °C. The reaction may be carried out neat or in a solvent. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, toluene, dimethylformamide and the like. One skilled in the art will recognize that the synthesis of compounds of formula I may require the construction of heterocycle. Methods include but are not limited to the use of a diamino compound and a carbonyl equivalent at 0 °C to 200 °C. The reaction may be carried out in aC1dic, basic or neutral conditions. Suitable solvents for the reaction are water, halogenated hydrocarbons, ethereal solvents, alcoholic solvents, toluene, ketones, dimethylformamide and the like. One skilled in the art will recognize that the synthesis of compounds of formula I may require the need for the protection of certain functional groups (i.e. derivatization for the purpose of chemical compatibility with a particular reaction condition). See, for example, Green et al, Protective Groups in Organic Synthesis. A suitable protecting group for an amine is methyl, benzyl, ethoxyethyl, t-butoxycarbonyl, phthaloyl and the like which can appended to and removed by literature methods known to those skilled in the art. One skilled in the art will recognize that the synthesis of compounds of formula I may require the construction of an amide bond. Methods include but are not limited to the use of a reactive carboxy derivative (e.g. aC1d halide) or the use of an aC1d with a coupling reagent (e.g. EDC1, DCC, HATU) with an amine at 0 °C to 100 °C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, dimethylformamide and alike. One skilled in the art will recognize that the synthesis of compounds of formula I may require the reduction of a functional group. Suitable reduC1ng reagents for the reaction include NaBH4, lithium aluminum hydride, diborane and the like at -20 °C to 100 °C. Suitable solvents for the reaction are halogenated hydrocarbons, ethereal solvents, and the like. The starting materials and the intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, C1ystallization, chromatography and alike. Such materials can be characterized using conventional means, including physical constants and spectral data. One method shown in Scheme 1, below, is for the preparation of compounds of formula IA wherein R1 is 1-benzimidazolyl or 2-benzamidazolyl and X is a bond or alkyl. Similar procedures can be used to prepare compounds wherein the benzene ring of the benzimidazolyl group is substituted, as well as the aza-benzimidazoles compounds (i.e., compounds wherein R1 is other than benzimidazolyl as defined above) and the benzoxazolyl and benzothiazolyl derivatives. Step a: A suitably monoprotected diamine of formula X, wherein X is a bond or alkyl, Prot is a protecting group, and the remaining variables are as defined above is alkylated or arylated with a halide. The intermediate diamine is then cyclized with an appropriate carbonyl or formyl equivalent to form a compound of formula XI Suitable protecting groups are methyl, benzyl, butoxycarbonyl, or ethoxycarbonyL A suitable halide for alkylation is a substituted aromatic compound or a substituted hetero-aromatic compound as desC1ibed by Henning et al, J. Med. Chem. 30, (1987), 814-819. Step b: The protected amine of formula XI is deprotected using methods known to those skilled in the art. A suitable method for methyl deprotection is reaction with a haloformate or the like. A suitable method for benzyl deprotection is cleavage with hydrogen at or above atmospheric pressure and a catalyst such as palladium. Suitable methods for carbamate deprotection are treatment with an aC1d, base or trimethylsilyl iodide. Step c: An amine of formula XII is reacted with an activated functional group Y of formula XIII to form the bond between the nitrogen and functional group Y in formula IA. When Y is a carbonyl group and M2 is carbon, activation can be via a halide (i.e, aC1d chloride intermediate) or other coupling reagents (EDC1, DCC, HATU, or like). Suitable reaction conditions may require a base such as triethylamine or N,N-diisopropylethylamine. Another method for the preparation of compounds of formula IA wherein R1 is 1-benzimidazolyl or 2-benzimidazolyl and X is a bond or alkyl is shown in Scheme 2, below. Similar procedures can be used to prepare compounds wherein the benzene ring of the benzimidazolyl group is substituted, as well as the aza-benzimidazoles compounds (i.e., compounds wherein R1 is other than benzimidazolyl as defined above). Step d: A suitably monoprotected diamine of formula X, wherein X is a bond or alkyl, Prot is a protecting group, and the remaining variables are as defined above, is alkylated or arylated with a halide to form a compound of formula XIV. Suitable protecting groups are methyl, benzyl, butoxycarbonyl, and ethoxycarbonyL A suitable halide for aikylation is a substituted aromatic compound or a substituted hetero-aromatic compound as desC1ibed by Henning et at. Step e: (1) The protected amine of formula XIV is deprotected using methods known to those skilled in the art. A suitable method for methyl deprotection is reaction with a haloformate or the like. A suitable method for benzyl deprotection is cleavage with hydrogen at or above atmospheric pressure and a catalyst such as palladium. Suitable methods for carbamate deprotection are treatment with an aC1d, base or trimethylsilyl iodide. (2) The resulting amine from Step e(1) is reacted with an activated functional group Y of formula XIII to form the bond between the nitrogen and functional group Y to obtain the compound of formula XV. When Y is a carbonyl group and M2 is carbon, activation can be via a halide (i.e. aC1d chloride intermediate) or other coupling reagents (EDC1, DCC, HATU, or the like). Suitable reaction conditions may require a base such as triethylamine, N.N-diisopropylethylamine, pyridine, or the like. Step f: After reduction of formula XV, the resulting compound is reacted with a carbonyl equivalent to give the cyclized compound of formula IA. The reduction conditions can be hydrogen in the presence of catalyst, metal in the presence of an aC1d or a base, or other reduction reagent. The cyclization can be performed in aC1dic or basic conditions. More detailed methods for synthesis of compounds are shown in Scheme 3 below. The preparation of compounds of formula IB wherein R1 is 1-benzimidazolyl (Methods A, B, C and F), Y is -C(O)- and R2 is substituted pyridyl, and compounds of formulas IC and IC wherein R1 is 2-benzimidazolyl (Methods D and E), Y is -C(O)-and R2 is substituted pyridyl are shown, but those skilled in the art will recognize that similar procedures can be used to prepare compounds wherein the benzene ring of the benzimidazolyl group is substituted, R2 is other than pyridyl, and aza-benzimidazoles compounds (i.e., compounds wherein R1 is other than benzimidazolyl as defined above). SpeC1fically exemplified compounds were prepared as desC1ibed in the examples below, from starting materials known in the art or prepared as desC1ibed below. These examples are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby. Unless otherwise stated, the following abbreviations have the stated meanings in the Examples below: Me=methyl; Et=ethyl; Bu=butyl; Pn=propyl; Ph=phenyl; t-BOC=tert-butyloxycarbonyl; CBZ=carbobenzyloxy; and Ac=acetyl DCC= dicyclohexylcarbodiimide DMAP=4-dimethyIaminopyridine DMF=dimethylformamide EDC1= 1 -(3-dimethyIaminopropyl)-3-ethylcarbodiimide ESMS=Electron spray mass spectroscopy FAB=Fast atom bombardment mass spectroscopy HATUlylyZ-AzabenzotriazoM-yllyN.N.N'ly'-tetramethyluronium hexafluorophosphate HOBT= 1-hydroxybenzotriazole LAH= lithium aluminum hydride LDA= lithium diisopropylamide NaBH(OAc)3= sodium triacetoxyborohydride NBS=N-bromosucC1nimide PPA= polyphosphoric aC1d RT=room temperature TBAF=tetrabutylammonium fluoride TBDMS=t-butyldimethylsi!yl TMEDA=N,N,N\N'-tetramethylethylenediamine TEMPO=2,2,6,6-tetramethyl-1-piperidinyloxy, free radical TLC=thin layer chromatography HRMS= High Resolution Mass Spectrometry LRMS= Low Resolution Mass Spectrometry nM= nanomolar Ki= DissoC1ation Constant for substrate/receptor complex pA2= -logECso, as defined by J. Hey, Ear. J. Pharmacol, (1995), Vol. 294, 329-335 C1/mmol= Curie/mmol (a measure of speC1fic activity) To a solution of 2-amino-4-methy!pyridine (10.81 g, 100 mmol) in tert-butanol (250 ml) was added t-BOC anhydride (26.19 g, 120 mmol). The reaction mixture was stirred at 23 °C overnight, and then concentrated to an oil. The C1ude product was dry loaded onto a silica gel column and flash chromatographed (eluant: 30% hexanes-CH2C(2 to 0-2% acetone-CH2C12) to produce 15.25 g (73.32 mmol; 73%) of the desired product as a white solid. To a solution of the product of Step 1 (35.96 g, 173 mmol) in THF (1.4 I) at -78 °C was added a n-BuLi solution (1.4 Mf 272 ml, 381 mmol) in hexanes portionwise over 30 min. The reaction mixture was then allowed to warm slowly and was stirred for 2 h at 23 °Cf which resulted in the formation of an orange preC1pitate. The mixture was then cooled back to -78 °C, and pre-dried oxygen (passed through a Drierite column) was bubbled through the suspension for 6 h while the temperature was maintained at -78 °C. The color of the reaction mixture changed from orange to yellow during this time. The reaction was quenched at -78 °C with (CHolyS (51A ml, 700 mmol) followed by AcOH (22 ml, 384 mmol) and allowed to warm with stirring to 23 °C. After 48 h, water was added and the product extracted into EtOAc. Purification by silica gel flash chromatography (eluant: 0-15% acetone/ CH2C12) provided 20.15 g (90 mmol; 52%) of the alcohol as a pale yellow solid. To a solution of the product of Step 2 (19.15 g, 85.5 mmol) in CH2C12 (640 ml) was added a saturated aqueous solution of NaHC03 (8.62 g, 103 mmol) and NaBr (444 mg% 4.3 mmol). The reaction mixture was cooled to 0 °C, and TEMPO (140 mg, 0.90 mmol) was introduced. Upon vigorous stirring,, commerC1al bleach solution (122 ml, 0.7 M, 85.4 mmol) (5.25% in NaOC1) was added portionwise over 40 min. After an additional 20 min at 0 °C, the reaction mixture was quenched with saturated aqueous Na2S203 and allowed to warm to 23 °C. Dilution with water and extraction with CH2C12, followed by concentration and flash chromatography (eluant: 30% hexanes-CH2C12 to 0-2% acetone-CH2C12) afforded 15.97 g (71.9 mmol; 84% yield) of the aldehyde as an off-white solid. To a solution of the product of Step 3 (11.87 g, 53.5 mmol) in CH2C12 (370 ml) was added ethyl isonipecotate (9.07 ml, 58.8 mmol) followed by four drops of AcOH, The reaction mixture was then stirred for 40 min at 23 °C, after which NaB(OAc)3H (22.68 g, 107 mmol) was added. The reaction mixture was stirred overnight at 23 °C, neutralized with saturated aqueous NaHCC>3, diluted with water and extracted with CH2C12. Concentration of the organic extracts, followed by silica gel flash chromatography (eluant: 0-4% sat. NH3 in CH3OH-CH2C12) provided 19.09 g (52.6 mmol; 98%) of the ester as an off-white solid. Step 5: To a solution of the product of Step 4 (1.57 g, 4.33 mmol) in THF-water- CH3OH (10 ml of a 3:1:1 mixture) was added LiOH monohydrate (0.125 g, 5.21 mmol). The reaction mixture was stirred overnight at 23 °CF concentrated and exposed to high vacuum to obtain 1.59 g of C1ude title compound as a yellowish solid which was used without purification. A solution of diamine 1B (see Method A, Step 1) (20gr 71.1mmol) and Et3N (30 ml, 213 mmol) in CH2C12 (400 ml) was cooled to 0 °C in an ice-water bath. To the well-stirred solution was added triphosgene (14.2 g, 47.3 mmol) cautiously (exotherm!) and portionwise over a period of 30 min. When addition was complete, stirring was continued at 0 °C for 1 h, then at RT for 16 h. The mixture was washed with 0.5N NaOH (200 ml), the organic layer was dried over anhydrous MgS04 and concentrated under vacuum. Hot EtOAc (200 ml) was added to the semi-solid residue, and the resultant mixture was cooled to RT, Filtration yielded compound P2-1 as a white solid (16.5g); and silica gel flash chromatography [CH2Ct2/CH3OH (2N NH3) = 40:1] of the filtrate provided additional product as a white solid (2.7 g) [combined yield: 88%]. FABMS: 308 (MH+; 100%), POC13 (100 ml) was added to P2-1 (17.2 g; 56 mmol) in a round-bottomed flask flushed with dry N2. The mixture was placed in an oil bath heated to 108 °C and was maintained at reflux for 6 h. POC13 was then removed in vacuo. The residue was adjusted to pH ~ 9-10 with 7N methanolic ammonia and was concentrated to dryness under vacuum. CH2C12 was added to the residue, insoluble material was filtered off, and the filtrate was again concentrated in vacuo. The residue was C1ystallized from EtOH to obtain compound P2-2 as a white solid (12.6 g; 67%). ES-MS: 326.1 (MH+; 100%). Varying amounts of compound P2-10 may be formed in this process and can be converted to desired product P2-2 by careful in situ treatment in CH2C12 solution at 0 °C with one equivalent each of EtOH and NaH, followed by workup with ice-water and CH2C12. Low temperature is maintained in order to minimize reaction at the 2-position of the benzimidazole nucleus. Sodium thiomethoxide (1.05 g; 15.0 mmol) was added to DMF (15 ml) in a round-bottomed flask flushed with N2. After stirring at RT for 30 min, solid chloride P2-2 (3.25 g, 10 mmol) was added, and the resultant mixture was kept stirring at RT for 16 h. EtOAc (100 ml) and water (50 ml) were added to the reaction mixture. The aqueous layer was separated and further extracted with EtOAc (50 ml). The combined extracts were dried over anhydrous MgS04 and concentrated under vacuum. The residue was purified via flash chromatography on silica gel, eluting with EtOAc-hexanes (3:4), to obtain compound P2-3 as a white solid (2.12 g; 63%). FABMS: 338.3 (MH+; 100%). Step 4 : To a stirred solution of P2-3 (300 mg, 12.5 mmol) in EtOH (40 ml)-isopropyl alcohol (40 ml) was added 25% (w/w) aqueous NaOH solution (20 ml). The resultant mixture was stirred at 85 °C for 24 h, then at 100 °C for an additional 4 h. Alcohols were removed under vacuum, and the aqueous residue was extracted sequentially with CH2C12 (2 x 40 ml), then EtOAc (30 ml). Combined extracts were dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (CH2C12/2N methanolic ammonia = 12:1) to obtain Preparation 2 as an off-white solid (2.85 gf 70%). ES-MS: 266 (MH+; 100%). NaH (60 mg of a 60% dispersion; 1.48 mmol) was added to CH3OH (4 ml) in a flask charged with N2. After stirring at RT for 30 min, chloride P2-2 (400 mg, 1.23 mmol) was added, and the resultant mixture was stirred at RT for 16 h. CH3OH was removed in vacuo, and to the residue were added CH2C12 (30 ml) and water (TO ml). The organic layer was dried over anhydrous MgS04, filtered, and the filtrate concentrated under vacuum. The residue was purified via flash chromatography on silica gel, eluting with EtOAc-hexanes (3:2) to obtain P3-1 as a white foam (0.232g; 59%). ES-MS: 322.1 (MH+; 100%). Step 2: 1N aqueous KOH (4.82 mL; 4.82 mmol) was added to a solution of P3-1 in EtOH (15 ml), and the resultant mixture was stirred at 80 °C for 48 h. The mixture was concentrated under vacuum. Water (3 ml) and CH2C12 (15 ml) were added to the residue, and the organic layer was separated and dried over anhydrous MgSC>4. Drying agent was filtered, and the filtrate was concentrated in vacuo to obtain Preparation 3 as a colorless glass (160mg; 95%). FABMS: 250.2 (MH+; 100%). P2-2 (300 mg; 0.923 mmol) and morpholine (3 ml) were mixed in a round-bottomed flask under N2, and the resultant mixture was heated to 80 °C for 16 h. Morpholine was removed under vacuum, and the residue was dissolved in CH2C12 (20 ml). An insoluble white preC1pitate was filtered off, and the filtrate was concentrated and purified by means of flash chromatography on silica gel, eluting with CH2C12/2N methanolic ammonia (45:1), to obtain P4-1 as a colorless glass (0.325g; 94%). ES-MS: 377.1 (MH+;100%). Step 2: Trimethylsilyl iodide (240 miC1oliters; 1.64mmol) was added to a solution of P4-1 (316 mg; 0.843 mmol) in CHC13 (2 ml) under N2, and the resultant solution was stirred at 55 °C for 7 h. The reaction was quenched with EtOH (2 ml), and the' mixture was concentrated to dryness under vacuum. The residue was basified with a 1:1 (v/v) mixture of concentrated NH4OH and water to pH -10 and extracted with CH2C12 (2x5 ml). The combined extracts were dried over anhydrous MgSCU. Drying agent was filtered, and the filtrate was concentrated under vacuum. The residue was purified via flash chromatography on silica gel, eluting with CH2C12-2N methanolic ammonia (13:1), to obtain compound Preparation 4 as a colorless glass. (181 mg; 70%). ES-MS: 305.1 (MH+; 100%). A solution of P5-1 (3.5 g, 21 mmol) and P5-2 (6.5 g, 38 mmol) in CH2Cl2 (3 ml) was heated to 110° C for 24 h and RT for 24 h. The reaction was diluted with CH2C12, washed with water and brine, and dried (Na2S04). Purification on a flash column (Si02,40% to 60% EtOAc in hexanes) gave P5-3 (1.3 g, 21%; M+H = 295). Step 2: To a solution of P5-3 (1.3 g, 4.4 mmol) in CH3OH (30 ml) was added Ra-Ni (0.5 g) and the mixture was hydrogenated under a H2 atmosphere (50 psi) for 18 h. Filtration through a pad of celite gave P5-4 as a grey solid that was used without further purification (1.05 g, 90%; M+H = 265). Step 3: A solution of P5-4 (1.05 g, 3.97 mmol), P5-5 (0.49 g, 3.97 mmol), DEC (1.14 g, 5.96 mmol) and HOBT (0.8 g, 5.96 mmol) in CH2C12 (10 ml) were stirred for 18 h at RT. The C1ude reaction mixture was diluted with additional CH2C12 and washed with 5% aqueous NaOH and brine and dried (Na2S04). Purification using flash chromatography (SiO, 8% EtOAc in hexane to 10% CH3OH in EtOAc) gave P5-6 (0.35 g, 24%; M+H = 370). Step 4: Compound P5-6 (0.7 g, 1.89 mmol) was dissolved in HOAc (10 ml) and heated to 120° C for 3.5 h. The reaction was cooled to RT, concentrated in vacuo, neutralized by the addition of 10% aqueous NaOH and extracted with CH2C12. The combined organic layers were dried (Na2S04j and concentrated to give P5-7 (0.58 g, 87%; M+H = 352) which was used in the next step without further purification. Step 5: A solution of P5-7 (0.58 g, 1.65 mmol) and NaOH (0.43 g, 13.2 mmol) in EtOH/H20 (9/1.10 ml) was heated to 100° C for 18 h. The reaction was cooled and concentrated and the residue purified on a flash column (Si02, 10% CH3OH saturated with ammonia in CH2C12) to give Preparation 5 (0.42 g, 91%; M+H = 280). A solution of compound P6-1 (prepared by procedures analogous to P2-1) (10.5 g, 36.2 mmol) and 2,6-di-terf-butylpyridine (12.2 ml, 54.4 mmol) in CH2C12 (400 ml) was treated with 1M sol. of Et30+BF4* (in CH2C12, 55 ml, 55 mmol). The reaction mixture was stirred at RT for 2h, quenched with 1N NaOH (100 ml), extracted with CH2C12 (3x), dried with Na2S04 and concentrated. Purification by silica gel chromatography (eluant: 5-10% acetone/ CH2C12) to give 6.37 g of P6-2 (20.0 mmol, 55%). Step 2: In a manner similar to that desC1ibed in Preparation 3f Step 2, P6-2 was converted to Preparation 6. A mixture of P7-1 (40gr 150 mmol), trimethyl orthoformate (66 ml, 64.0 g, 600 mmol) and a catalytic amount of p-toluenesulfonic aC1d monohydrate (300 mg, 1.58 mmol) was stirred under N2 at 120 °C for 3 h. Excess orthoformate was removed under vacuum. The residue was partitioned between EtOAc (200 ml) and 1N NaOH (100 ml). The organic layer was washed with brine (100 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (CH2C!2/CH3OH (2N NH3) = 45:1) to obtain P7-2 as a dark purple syrup (27.2 g, 66%), which solidified upon standing. ES-MS: 275 (MH+; 100%). NBS was added portionwise (exotherm) to a solution of P7-2 (27 g, 100 mmol) in CHC13 (300 ml), and the resultant solution was stirred at 60 °C for 16 h. Solvent was then removed under vacuum, and the residue was partitioned between EtOAc (200 ml) and 0.7N Na2S204 (250 ml). The organic layer was washed with brine (150 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography [CH2C12/acetone = 45:1] to obtain P7-3 as a yellow solid (24.2 g, 69%). ES-MS: 353 (MH+; 100%). Step 3: NaH (544 mg of a 60% dispersion, 13.6 mmol) was added to a solution of CH3OH (0.551 ml, 436 mg, 13.6 mmol) in DMF (5 ml). The resultant mixture was stirred at RT for 30 min before adding solid bromide P7-3 (3.99 g, 11.3 mmol). The reaction suspension was stirred at RT for 16 h. The mixture was then partitioned between EtOAc (800 ml) and water (40 ml). The aqueous layer was extracted with EtOAc (40 ml). Combined extracts were washed with brine (30 ml) and dried over anhydrous MgSC>4. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum to obtain Preparation 7 as a white syrup (2.81 g, 81%), which was used without further purification. ES-MS: 305 (MH+; 100%). A solution of 1B (15 g, 52.8 mmo!) and 1,1'-thiocarbonyldiimidazole (25 g, 140 mmol) in THF (300 ml) was stirred at 72 °C under N2 for 16 h, during which time a preC1pitate formed. THF was removed under vacuum, and the residue was purified by silica gel flash chromatography (CH2C12/acetone = 20:1) to obtain P8-1 as a light yellow solid (167 g, >95%). ES-MS: 324 (MH+; 100%). Step 2: To a stirred mixture of P8-1 (4.00 g, 12.5 mmol) and K2C03 (2.05 g, 13.6 mmol) in DMF (40 ml) under a N2 atmosphere was added CH3I (0.85 ml, 1.94 g, 13.6 mmol). The resultant mixture was stirred at RT for 16 h before partitioning between EtOAc (100 ml) and water (40 ml). The aqueous layer was extracted with EtOAc (40 ml). Combined extracts were washed with brine (30 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum to obtain Preparation 8 as a foamy white solid (4.20 g, >95%; contained a small amount of DMF), which was used without further purification. ES-MS: 338 (MH+; (Modified published procedure: G. Heinisch, E. Luszczak, and M. Pailer; Monatshefte furChemie, 1973 (104), 1372. P9-1 (4.5 g, 47.8 mmoles), P9-2 (8.12g, 76.5 mmoles), and anhydrous ZnC12 were heated, under N2, in a dry apparatus, at a bath temperature of 160 °C for 5 h. The resulting oil was purified by flash chromatography on silica gel using 30% Hexanes/EtOAc, yielding 5.92 grams (67%) of the product. Step 2: Os04 (5.0 ml in t-butanol, 2.5% w/w) was added to P9-3 (5.9 g, 32.38 rrirnoles) dissolved in p-dioxane (87 ml) and water (29 ml). Nal04 (14.1 g, 65.92 mmoles) was added, with good stirring, in small portions, over a period of 6 h. The mixture was then diluted with p-dioxane and filtered. After removing most of the solvent under reduced pressure, the residue was taken in CH2C12 (600 ml) and dried over anhydrous Na2S04. After removal of the solvent, the mixture was purified by flash chromatography on silica gel using 5% CH3OH/CH2C12 as eluent to obtain Preparation 9. Yield: 2.89 g (82%). A solution of P10-1 (2 g, 15 mmo!) in CH2C12 (50 ml) was treated with Et3N (3 g, 30 mmol) and triphenylmethyl chloride (TrC1, 4.25 g, 15.3 mmol) and stirred at RT overnight. The solvent was removed in vacuo and the residue purified via flash column chromatography (Si02, 20% EtOAc in hexane) to give P10-2 (5.2 g, 46%). Step 2: A solution of P10-2 (5.2 g, 14.6 mmol) in CC14 (80 ml) was treated with NBS (7.8 g, 43 mmol) and the reaction heated to 80° C overnight. The reaction was cooled, filtered and concentrated, and the residue was purified via flash column chromatography (Si02, 20% to 30% EtOAc in hexane) to give Preparation 10 (2.8 g, 42%, M+H = 453, 455) Step 1: To a stirred solution of P8-1 (6.5 g, 20.1 mmol) in EtOH (80 ml) was added 25% (w/w) aqueous NaOH solution (20 ml). The resultant mixture was stirred at 90 °C for 16 h. EtOH was removed under vacuum, and the residue was adsorbed directly onto silica gel and subjected to flash chromatography (CH2C12/2N methanolic ammonia = 9:1) to obtain P11-1 as a white solid (4.46 g, 70%). ES-MS: 252 (MH+; 100%). Step 2: A mixture of P11-1 (3.95 g; 15 J mmol), BOC-isonipecotic aC1d (3.60 g; 15.7 mmol), HOBT (3.19 g; 23.6 mmol), DIPEA (3ml; 2.23g; 17.2 mmol) and EDC1 (4.50 g; 23.6 mmol) in DMF (30 ml) was stirred under N2 at RT for 16 h. The reaction mixture was partitioned between EtOAc (60 ml) and water (40 ml). The aqueous phase was extracted with EtOAc (40 ml), and the combined extracts were washed with brine (40 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (CH2C12/CH3OH (2N NH3) = 40:1) to obtain P11-2 as a white solid (-7.3 g, -100%), containing a small amount of DMF, used without further purification in Step 3 below. ES-MS: 463 (MH+; 70%); 407 (100%). To a stirred mixture of P11-2 (460 mg; 1 mmol)and K2C03(165mg; 1.20 mmol) in DMF (4 ml) under a N2 atmosphere was added Etl (92 miC1oliters; 179 mg; 1.15 mmol). The resultant mixture was stirred at RT for 16 h and was then partitioned between EtOAc (20 ml) and water (10 ml). The aqueous phase was extracted'with EtOAc (10 ml), and the combined extracts were washed with brine (20 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum to obtain P11-3 as a pale yellow foam (471 mg, 96%), containing a small amount of DMF, used without further purification in Step 4 below. ES-MS: 463 (MH+; 85%); 435 (100%). Step 4: To a solution of P11-3 (465 mg; 0.949 mmol) in CH2C12 (4 ml) was added TFA (1 ml; 1.54 g; 13.5 mmol). The resultant solution was stirred for 2 h at RT and was then partitioned between CH2C12 (20 ml) and 1:1 (v/v) concentrated NH4OH:water (5 ml). The aqueous phase was extracted successively with 95:5 CH2CL2:EtOH (5 ml) and EtOAc (5 ml). The combined extracts were dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum to obtain Preparation 11 as a pale white foam (353 mg, 95%), used without further purification. ES-MS: 391 (MH+; 100%). A mixture of a (25 g, 0.16 mol), b (27 g, 0.16 mol), K2C03 (26 g, 0.19 mol), and Nal (2.4g, 0.016 mol) in dimethylacetamide (50 ml) was heated at 140 °C for 3.5 h. The reaction mixture was concentrated to one-third volume, poured onto saturated aqueous NaHC03 and extracted with EtOAc (4x). The combined organic layers were washed with water (2*) and brine, dried over Na2S04, and concentrated. ReC1ystallization with EtOH provided 1A (48 g, 98%). A suspension of 1A (20.00 gf 64.2 rnmol,) and Raney® 2800 Nickel (5.0 g) in ethanol (70 ml) and THF (140 ml) was shaken under H2 (40 psi) for 2 h. The mixture was filtered through a short pad of celite. The filtrate was concentrated and dried on vacuum to deliver a tan solid (18.20 g, -100%). A solution of 1B (5.00 g, 17.77 mmol) and picolinoyl chloride hydrochloride (3.16g, 17.75 mmol) in CH2C12 (400 ml) and Et3N (15 ml) was stirred at RT. After 15 h, the reaction was diluted with CH2C12, washed with water, dried over Na2SC>4, concentrated, and dried on vacuum to provide a brown foam (6.47g, 94%). A solution of 1C (1.77g, 4.58 mmol) in ethanol (50 ml) and concentrated H2S04 (5.0 ml) was refluxed for 3 h, cooled to RT, and neutralized with 1.0 M NaOH until pH = 10. The resulting mixture was extracted with CH2C12. The combined organic solutions were dried over Na2S04 and concentrated on reduced pressure. The residue was purified by flash chromatography (silica gel, 5% CH3OH in CH2C12as eluent) to provide a tan foam (1.58g, 94%). lodotrimethylsilane (6.30g, 31.48 mmol) was added to a solution of 1D (3.88g, 10.53 mmol) in anhydrous 1,2-dichloroethane (40 ml). The resulting solution was stirred at 75 °C for 4 hours, cooled to RT, and treated with 1.0 M NaOH solution. The mixture was then extracted with CH2C12. The combined extracts were washed with water, dried over Na2S04, and the solvent evaporated. Purification of the residue by flash chromatography (silica gel, 10% CH3OH in CH2C12as eluent) delivered an off-white foam (2.10g, 67%). Amine 1E (5.80g, 19.6 mmol) and Preparation 1 (5.32gf 23.4 mmol) were dissolved in DMF (60 ml) and CH2C12 (60 ml). To the resulting solution, EDC1 hydrochloride (5.70g, 24.50 mmol), HOBT (1.30g, 24.50 mmol), and diisopropylethylamine (5.08g, 39.6 mmol) were added successively. The resulting reaction mixture was stirred at 70°C for 4 hours, cooled to RT, diluted with CH2C12, washed with water, dried over Na2S04, and concentrated. Flash chromatography (Si02, 5% CH3OH in CH2C12 -► 90:10:0.5 CH2C12:CH3OH:NH4OH) of the residue provided a tan foam (7.89g, 65%). Step 6: A solution of 1F (7.89g, 12.88 mmol) and TFA (29g, 257 mmol) in CH2C12 (65 ml) was stirred at RT for 12 h, neutralized with 1.0 M NaOH, and extracted with CH2C12. The combined organic layers were washed with water, dried over Na2SO4 and concentrated. Purification of the C1ude product by flash chromatography (Si02, 5% CH3OH in CH2C12 to 90:10:0.5 CH2Cl2:CH3OH:NH4OH) provided the title compound as a white solid (5.80g, 88%). MS: 514 (MH+). TFA (200 ml, 2.596 mol) was added to a solution of 2A (20g, 51.36 mmol) in CH2C12 (100 ml). The resulting reaction mixture was stirred at RT for 6 h, neutralized with 1.0 M NaOH, and extracted. The combined extracts were washed with water, dried over Na2S04, and concentrated. Flash chromatography gave an orange solid (13.50g, 91%). Amine 2B (1.50g, 5.19 mmol) and Preparation 1 (1.75g, 5.13 mmol) were dissolved in DMF (10 ml) and CH2C12 (10 ml). To the resulting solution, EDC1 hydrochloride (1.50g, 7.83 mmol), HOBT (1.05g, 7.82 mmol), and diisopropylethylamine (3.71g, 28.70 mmol) were added successively. The resulting reaction mixture was stirred at 70°C for 18 h, cooled to RT, diluted with CH2C12, washed with water, dried over Na2SO4, and concentrated. Flash chromatography of the residue provided an orange gel (2.31 g, 74%). A suspension of 2C (2.10 g, 3.46 mmol,) and Raney® 2800 Nickel (1.0 g) in CH3OH (100 ml) was shaken under H2 (30 psi) for 6 h. The mixture was filtered through a short pad packed with celite. The filtrate was concentrated and dried on vacuum to deliver an orange solid (1.80 g, 90%). Amine 2D (200 mg, 0.347 mmol) and picolinoyl chloride hydrochloride (62 mg, 0.348 mmol) were dissolved in CH2CI2. Et3N was then introduced via a syringe. The resulting solution was stirred at RT for 6 h, treated with 1.0 M NaOH solution, and extracted. The extracts were washed with water, dried over Na2S04, and concentrated. Purification of the residue by flash chromatography gave a white foam (167 mg, 71% yield). Step 5: A solution of 2E (160 mg, 0.235 mmol) and H2S04 (concentrated, 0.50 ml) in ethanol (10 ml) was refluxed for 2.5 h, cooled to RT, and neutralized with 1.0 M NaOH. After extraction of the mixture, the combined organic layers were washed with water, dried over Na2S04, and concentrated. Purification of the crude product using prep TLC (10% CH3OH in CH2CI2) provided the title compound as a white solid (88 rig, 66%). MS: 564 (MH+) Diamine 3A (1.43 g, 10 mmol) and isonipecotic acid 3B (1.29 g, 10 mmol) were nixed, and PPA (20 g) was added. The resulting mixture was heated at 180 °C for 3.5 i, cooled to RT and diluted with water to 100 ml. The solution was then basified with solid NaOH to pH 14. The resultant copious precipitate was filtered off. The precipitate vas washed repeatedly with CH3OH, and combined CH3OH extracts were concentrated-dry loaded on silica gel and flash chromatographed (25-40% 5N NH3 in :H3OH/ CH2CI2) to provide 3C as a dark solid (1.90 g, 81%). To the mixture of aC1d 3D (181mg, 0.54 mmol), HATU (247 mg, 0.65 mmol) and Et3N (84 nl, 0.6 mmol) in DMF (12 ml) was added amine 3C (126 mg, 0.54 mmol). The resulting mixture was stirred at RT for 24 h, concentrated, redissolved in CH3OH, concentrated-dry loaded on silica gel and flash chromatographed (5-10% 5N NIH3 in CH3OH/ CH2C12) to provide 3E as a yellow oil (210mg, 70%). Step 3: A solution of 3E (96 mg, 0.174 mmol) in 15 ml of 1M HC1 in 25% CH3OH/ dioxane was stirred at RT for 48 h. The mixture was concentrated, exposed to high vacuum, redissolved in CH3OH, concentrated-dry loaded on silica gel and flash chromatographed (10-15% 5N NH3 in CH3OH/ CH2C12) to provide the title compound as a colorless oil (48 mg, 61%). MS: 453 (MH+) A mixture of neat 4A (1.75g, 6.66 mmol) and 4B (2.93g, 15.07 mmol) was stirred at 120 °C for 2 days, cooled to RT, treated with 1.0 M NaOH solution (30 ml), and extracted with EtOAc. The combined organic layers were washed with water and dried over Na2S04. After evaporation to dryness, the C1ude residue was flash chromatographed (silica gel, 50% EtOAc in hexanes as eluent) to give 510 mg of 4C To a 500 ml pressure bottle was added 4C (490 mg, 1.18 mmol) in CH3OH (20 ml). Under N2 stream, palladium hydroxide (300 mg, 20 wt.% on carbon) solid was added. The reaction mixture was shaken under 55 psi of hydrogen for 40 h and filtered. The filtrate was concentrated and dried on vacuum to deliver a yellow solid (340 mg. 88%). To a 50 ml round-bottomed flask were successively added 4D (287 mg, 0.88 mmol), Preparation 1 (300 mg, 0.88 mmol), EDO hydrochloride (210 mg, 1.10 mmol), HOBT (149 mg, 1.10 mmol), and diisopropylethylamine (228 mg, 1.76 mmol). DMF (3 ml) and CH2C12 (3 ml) were introduced via a syringe. The resulting reaction mixture was stirred at 70 °C for 15 h and cooled to RT. After addition of 1 N NaHCC>3 solution, the resulting mixture was extracted with CH2C12. The combined organic solutions were dried over Na2S04 and concentrated. Purification of the C1ude product by flash chromatography on silica gel with 10% CH3OH in CH2C12 as the eluent provided 4E as a solid (231 mg.41%). Step 4: To a 25 ml round-bottomed flask was added 4E (200 mg, 0.31 mmol) in CH2C12 (2.5 ml). TFA was then introduced via a syringe. The resulting solution was stirred at RT for 15 h, diluted with CH2C12, neutralized with 1.0 M NaOH solution, and separated. The organic solution was washed with water and dried over Na2S04. After evaporation of the solvent, the C1ude product was purified on a preparative TLC plate with 10% CH3OH in CH2C12 as the eluent to provide the title compound as a white solid (85 mg, 50%). MS: 544 (MH+). A solution of compound 5A (100g, 0.389 mol) in THF (400 ml) was added dropwise over 1.0 h to a solution of LDA (233 mL, 2.0 M in THF/heptane/ethyl- benzene, 0.466 mol) in THF (300ml) at 0 °C. The red-orange solution was stirred at 0 X for 30 min, and then transferred by cannula to a pre-cooled (0 °C) solution of N-fluorobenzenesulfonimide (153 g, 0.485 mol) in dry THF (600 ml). The reaction mixture was stirred at 0 X for 30 min, and then at 20 °C for 18 h. The total solvent volume was reduced to approximately one third, and EtOAc (11) was added. The solution was washed successively with water, 0.1 N aq. HC1, saturated aq. NaHC03, and brine. The organic layer was dried over MgS04, filtered, and concentrated under reduced pressure to yield a C1ude liquid. Separation by flash chromatography (6:1 hexanes-EtOAc) gave compound 5B (93.5 gt 87%). A solution of 5B (50g, 0.181 mol) in THF (300 ml) and CH3OH (200 ml) was treated with a solution of LiOH-H20 (9.2 g, 0.218 mol) in water (100 ml) and then heated to 45 X for 6 h. The mixture was then concentrated and dried in vacuo to provide 5C (45 g, 100%). Compound 5C (20.4 g, 0.081 mol) was added slowly to a stirred flask of CH2C12 (250 ml) at 20 X. The resulting white slurry was cooled to 0 X and treated slowly with oxalyl chloride (6.7 ml, 0.075 mol) and a drop of DMF. After stirring at 20 X for 0.5 h, the mixture was concentrated and dried in vacuo to provide 5D. Step 4A: A mixture of c (64 g, 0.40 mol), d (84 ml, 0.52 mol), and K2C03 (66 g, 0.48 mol) in anhydrous toluene (350 ml) was heated at reflux overnight. The reaction mixture was diluted with CH2C12, washed three times with 5% aqueous NaOH, dried over Na2SC>4, and concentrated. ReC1ystallization with MeOH provided e (121 g, -100%) as a yellow solid. A suspension of e (121 g, 0.41 mol) and Raney Nickel (10 g) in EtOH (400 ml) was shaken under H2 (40 psi) for 4 h. The mixture was filtered through a short pad of Celite (washing with CH3OH). The filtrate was concentrated and dried in vacuo to provide f (109 g, -100%) as a dark brown solid. A solution of f (109 g, 0.41 mol) in CH2C12-DMF (1:1, 500 ml) was treated with picolinic aC1d (61 g, 0.50 mol), EDC1 (119 g, 0.62 mol), HOBt (84 g, 0.62 mol) and iPr2NEt (141 ml, 1.03 mol). The mixture was stirred at 70 °C for 6 h and then overnight at 20 °C. The reaction mixture was diluted with EtOAc, washed 3 times with 5% aqueous NaOH, dried over Na2SO4, and concentrated. Flash chromatography (0-100% EtOAc/hexane) provided g (131 g, 86%). A solution of g (131 g, 0.36 mol) in AcOH (200 ml) was heated at 120 °C overnight. The reaction mixture was cooled, carefully basified with 5% aqueous NaOH and extracted with CH2C12. The combined organic extracts were dried over Na2S04 and concentrated. Flash chromatography (0-80% EtOAc/hexane) provided h (95 g, 76%) as a yellow solid. A solution of h (95 g, 0.27 mol) in anhydrous CHC13 (300 ml) was treated with iodotrimethylsilane (272 g, 1.36 mol) and heated at 70 °C for 5 h. The reaction mixture was cooled, quenched with cold 10% aqueous NaOH, and extracted with CH2C12. The combined organic extracts were dried over Na2S04 and concentrated. Flash chromatography (2N NH3-CH3OH/EtOAc) provided 5E (43 g, 57%) as a pale yellow solid. A mixture of 5D (0.075 mol) in CH2C12 (250 ml) was treated with 5E (15 gf 0.054 mol) and iPr2NEt (25 ml, 0.135 mol) while maintaining a temperature of 20 °C. After 1 h, the mixture was concentrated and then stirred in CH3OH (200 ml)/CH2C12 (200 ml)/H20 (1 ml) for 1 h at 20 °C. The solvent was then evaporated. Treatment with TFA (200 ml) in CH2C12 (250 ml) at 20 °C followed by flash chromatography (0-7% 7N NH3-CH3OH/CH2C12) provided 5F (80-90% from 5C). A solution of 5F (0.41 g, 1.0 mmol) in CH2C12 (20 ml) was treated with 5G (0.31 g, 2.5 mmol, JP Patent 63227573, 1988), NaBH(OAc)3 (0.53 g, 2.5 mmol) and few drops of AcOH and then stirred overnight at 20 °C. The mixture was partitioned between 10% NaOH and CH2C12. The organic layer was dried with Na2S04 and concentrated. Flash chromatography (0-5% 7N NH3-CH3OH/CH2C12) provided the A solution of 5G (50 g, 0.41 mol) in CH3OH (300 ml) was cooled to 0 °C and carefully treated with NaBH4 (20g, 0.53 mol in 6 batches) over 20 min. The reaction was then allowed to warm to 20 °C and was stirred for 4 h. The mixture was again cooled to 0 °C, carefully quenched with saturated aqueous NH4Cl, and concentrated. Flash chromatography (5-10% 7N NH3-CH3OH/CH2C12) provided 5H (31g, 62%) as a light yellow solid. A slurry of 5H (31 g, 0.25 mol) in CH2C12 (500 ml) was cooled to 0 °C and slowly treated with SOC12 (55ml, 0.74 mol over 30 min). The reaction was then stirred overnight at 20 °C. The material was concentrated, slurried in acetone, and then filtered. The resulting beige solid 51 was dried overnight in vacuo (38.4g, 52%, HC1 salt). A homogeneous solution of 5F (16.4 g, 40 mmol) in anhydrous DMF (200 ml) was cooled to 0 °C, carefully treated with NaH (8g, 200 mmol), and stirred at 20 °C for 20 min. The reaction mixture was then cooled to 0 °C, treated with Nal (6g, 40 mmol) and 51 (14.5g, 80 mmol)t and then stirred overnight at 20 °C. The reaction was diluted with CH2C12(500 ml), washed with 1N aqueous NaOH, washed with brine, filtered through Celite, and concentrated. Flash chromatography (0-4% 7N NH3-CH3OH/CH2C12) provided Ex. 5 (16.9g, 82%) as a beige solid. To a stirred solution of diamine 1B (1,0g, 3.55 mmol) in C2H5OH (25 ml), at RT was added portionwise solid CNBr (564 mg; 5.33 mmol). The resultant solution was allowed to stir at RT for 5 days before removing solvent under vacuum. The residual oil was partitioned between EtOAc (30 ml) and 2M Na2C03 (10 ml). The aqueous layer was adjusted to pH -10 by addition of a few drops of 6N NaOH and was then re-extracted with EtOAc (2x10 ml). Combined extracts were washed with brine (5 ml) and filtered through anhydrous MgSO4. The filtrate was stripped in vacuo to obtain compound 6A as brown powder (1.03 g; 94%) suffiC1ently pure for use without purification. FABMS: 307 (MH+; 100%). In a dry flask, under an inert atmosphere, a mixture of compound 6A (369 mg; 1.20 mmol) and CH2C12 (11 ml) was stirred and sonicated until the formation of a clear, amber solution to which was added via syringe 4-fluorophenyl isocyanate (158 miC1oliters; 190 mg; 1.38 mmol). After 30.5 hat RT, a few drops of CH3OH were added to the reaction solution, and solvent was removed under vacuum. The residual solid was dissolved in boiling Et2O (-30 ml). Insoluble matter was filtered, and the filtrate was diluted to a volume of -60 ml with hot hexanes. The solution was concentrated on a steam bath to a volume of -30 ml, by which point preC1pitation had begun. The mixture was allowed to stand at RT for -3 h. Filtration and washing with Et20-hexanes (1:1 v/v) yielded compound 6B as a reddish-brown powder (394 mg; 74%). FABMS: 444 (MH+; 100%). Although TLC and NMR indicated the presence of minor impurities, the product was suffiC1ently pure for use in Step 3 below. To a stirred suspension of compound 6B (333 mg; 0.751 mmol) in CHCb (2 ml), contained in a flask equipped for reflux under an inert atmosphere, was added via syringe (CFblySil (214 miC1oliters; 301 mg; 1.51 mmol). Solids dissolved rapidly to produce a dark reddish-brown solution. Stirring was continued at RT for 20 min before plaC1ng the reaction mixture in an oil bath preheated to 50 °C. After 5 h at 50 °C, a second portion of (CH3)3Sil (54 miC1oliters; 75 mg; 0.378 mmol) was added and heating continued at 50 °C for another 2.5 h. The reaction mixture (consisting of solid and solution phases) was removed from the heating bath and was treated with CH3OH (2.5 ml) added in two portions. The reaction mixture was stirred and warmed to 50 °C for a few minutes, allowed to cool and was then filtered. Collected solids were washed with 1:1 (v/v) CH3OH-EtOAc to obtain the hydriodide salt form of 6C as a pale reddish-brown powder (356 mg) wich was used in the next step without further purification. FABMS: 372 (MH+; 100%). To a stirred suspension of 6C (340 mg; 0.681 mmol), Prep. 1 (228 mg; 0.681 mmol), HOBT (9.2 mg; 0.0681 mmol) and NEt3 (379 miC1oliters; 275 mg; 2.72 mmol) in DMF (13 ml) was added solid EDC1 (163 mg; 0.851 mmol). The cloudy reaction mixture was placed in a preheated oil bath and was stirred at 50 °C for 30 min, after which the resultant clear, amber solution was stirred for 23.5 h at RT. A few drops of water were added, and the reaction mixture was concentrated at 60 °C under vacuum. The concentrate was partitioned between EtOAc (20 ml) and water (5 ml)-brine (2.5 ml). The aqueous phase was extracted with EtOAc (2x5 ml). Combined extracts were washed with brine (2.5 ml) and filtered through anhydrous MgS04. The filtrate was evaporated under vacuum, and the residue was purified by flash chromatography on silica gel, eluting with a gradient of CH2C12-CH3OH-NH4OH (97:3:0.5 -> 96:4:0.5). Product 6D (222 mg; 47%) was obtained as pale yellow powder. FABMS: 689 (MH+; -93%); 578 (-58%); 478 (100%). Step 5: To a solution of 6D (208 mg; 0.302 mmol) in CH2C12 (3 ml) was added TFA (928 miC1oliters; 1.37 g; 12.1 mmol) with swirling of the flask, which was then flushed with dry N2, sealed and allowed to stand at RT for 6 h. The reaction solution was evaporated under vacuum, and the residue was partitioned between EtOAc (20 ml) and 2M Na2CC3 (3 ml) plus suffiC1ent water to produce two clear phases. The aqueous phase was extracted with EtOAc (3x5 ml). Combined extracts were washed with brine (3 ml) and filtered through anhydrous MgS04. The filtrate was stripped of solvent in vacuo, and the residue was subjected to flash chromatography on silica gel, eluting with CH2ClrCH3OH-NH4OH (97:3:0.5). The title compound (130 mg; 72%) was obtained as pale yellow powder. FABMS: 589 (MH+; -64%); 478 (100%). Using procedures similar to those desC1ibed above, employing the appropriate starting materials, compounds in the following tables are prepared: A solution of 388B (0.66 g, 2.2 mmol) in DMF (15 ml) was treated with 5C (0.62 g, 2.5 mmol), 1-propanephosphonic aC1d cyclic anhydride (3.3 ml, 11.2 mmol, 50 wt. % in EtOAc) and N-ethylmorpholine (1.4 ml, 10.7 mmol). The mixture was stirred at 50 °C for 3h. The reaction mixture was concentrated and diluted with EtOAc. The solution was washed three times with 5% aqueous NaOH, dried over Na2S04, concentrated and subjected to flash chromatography (10% 2N NH3-CH3OH/EtOAc). The material was then taken up in CH2C12 (20 ml) and treated with 4 M HC1-dioxane (4 ml). After stirring overnight at 20 °C, the reaction was carefully basified with 10% aqueous NaOH and extracted with CH2C12. The combined organic layers were dried over Na2S04, concentrated and subjected to flash chromatography (30% 2N NH3-CH3OH/EtOAc) to provide 388C as a white solid (0.08g, 10%). To a stirred, cloudy solution of 389A (300 mg, 1.14 mmol) in THF (15 ml) were added a solution of 389B (292 mg, 1.37 mmol) in THF (1 ml), followed by NaBH(OAc)3 (483 mg, 2.28 mmol). After stirring at RT for 39 h, TLC revealed the presence of unchanged starting materials in the cloudy white reaction suspension. Therefore, another quantity of NaBH(OAc)3 (242 mg, 1.14 mmol) was added and stirring at RT continued for a total of 113 h. The reaction mixture was then filtered and collected solids washed thoroughly with CH2C12. The combined filtrate and washings were stripped of solvent under vacuum, and the residue was partitioned between EtOAc (60 ml) and a solution consisting of water (2.5 ml), 2M Na2C03 (6.5 ml) and 6N NaOH (5 mi). The aqueous layer was further extracted with EtOAc (3x15 ml). The combined extracts were washed with brine (5 ml) and dried over anhydrous MgS04. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by silica gel flash chromatography (EtOAc/hexanes = 1:1) to obtain 389C as a mixture of colorless gum and white foam (368 mg, 70%), homogeneous to TLC, which solidified upon standing. ES-MS: 461 (MhT; 100%). F To a stirred, ice-cold solution of 389C (358 mg, 0.777 ml) in CH2C12 (7 ml) was added via syringe cold, neat TFA (576 miC1oliters, 886 mg, 7.77 mmol). The resultant solution was stirred in an ice-water bath for 30 min, then at RT for 29.5 h. Volatiles were removed under vacuum, and the gummy residue was triturated (magnetic stirrer) with Et20 (35 ml) for 16 h. Filtration and washing with Et20 yielded the bis- trifluoroacetate salt of 389D as a white powder (449 mg, 98%). Step 3: To a stirred suspension of 389D (100 mg, 0.170 mmol) in CH2C12 (5 ml) was added Et3N (47.4 miC1oliters, 34.4 mg, 0.340 mmol), whereupon all solids dissolved. To the stirred solution were then added 5G (25.1 mg, 0.204 mmol), followed by NaBH(OAc)3 (72.1 mg, 0.340 mmol). After stirring at RT for 66 h, TLC revealed the presence of unchanged starting materials in the light yellow reaction suspension. Therefore, another quantity of NaBH(OAc)3 (72.1 mg, 0.340 mmol) was added and stirring at RT continued for a total of 90 h. The reaction mixture was then filtered and ' collected solids washed thoroughly with CH2C12. The combined filtrate and washings were stripped of solvent under vacuum, and the residue was partitioned between EtOAc (20 ml) and a solution consisting of water (0.6 ml), 2M Na2C03 (1.5 ml) and 6N NaOH (1.2 ml). The aqueous layer was further extracted with EtOAc (3x5 ml). The combined extracts were washed with brine (2 ml) and dried over anhydrous MgSO-*. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by preparative TLC (silica gel; CH2C12/CH3OH/conc. NH4OH = 90:9:1) to obtain the title compound as a light beige foam (36 mg, 45%). FABMS: 468 (MH+; 100%). 4-[[4-[2-(5-methyl-3-isoxazoly!)-3H-imidazo[4?5-b]pyridine-3-yl]-1-(4-piperidinylcarbonyl)piperidine (0.99 g, 2.51 mmoles) and pyridazine 4-carboxaldehyde (0.35 g, 3.26 mmoles) were stirred at RT in dry CH2C12 (25 ml) containing activated 3A molecular sieves (6.5 g). After 5 h, triacetoxy borohydride (3.2 g, 15 mmoles) was added and the mixture was stirred for 70 h. The mixture was diluted with CH2C12 and the solid filtered through a pad of Celite. The filtrate was stirred for 20 min. with saturated aqueous NaHC03, then separated, washed with brine, and dried over anahydrous Na2S04. The reaction mixture was purified by preparative TIC. The plates were eluted with EtOAc:Hexanes:CH3OH(NH3) (75:20:5). Extraction of the bands with 13% CH3OH(NH3)/EtOAc gave a mixture of Example 665 and Example 496. Example 658: MS (M+H): 423. In a similar manner, using 4-[[4-[2-(methylthio)-3H-imidazo[4f5-b]pyridine-3-yl]-1-(4-piperidinylcarbonyl)piperidine (0.88 gr.;2.44 mmoles), pyridazine 4-carboxaldehyde (0.34 g, 3.18 mmoles), and triacetoxy borohydride, a mixture of Example 666 and Example 495 was prepared: General Procedure for H3-Receptor Binding Assay The source of the H3 receptors in this experiment was guinea pig brain. The animals weighed 400-600 g. The brain tissue was homogenized with a solution of 50 mM Tris, pH 7.5. The final concentration of tissue in the homogenization buffer was 10% w/v. The homogenates were centrifuged at 1,000 x g for 10 min. in order to remove clumps of tissue and debris. The resulting supernatants were then centrifuged at 50,000 x g for 20 min. in order to sediment the membranes, which were next washed three times in homogenization buffer (50,000 x g for 20 min. each). The membranes were frozen and stored at -70°C until needed. All compounds to be tested were dissolved in DMSO and then diluted into the binding buffer (50 mM Tris, pH 7.5) such that the final concentration was 2 pg/ml with 0.1% DMSO. Membranes were then added (400 pg of protein) to the reaction tubes. The reaction was started by the addition of 3 nM [3H]R-a-methyl histamine (8.8 C1/mmol) or 3 nM [3H]Na -methyl histamine (80 C1/mmol) and continued under incubation at 30°C for 30 min. Bound ligand was separated from unbound ligand by filtration, and the amount of radioactive ligand bound to the membranes was quantitated by liquid sC1ntillation spectrometry. All incubations were performed in duplicate and the standard error was always less than 10%. Compounds that inhibited more than 70% of the speC1fic binding of radioactive ligand to the receptor were serially diluted to determine a Kj (nM). General Procedure for rHu H3 Binding Assay [3H]N*-methylhistamine (82 C1/mmole) was obtained from Dupont NEN. Thioperamide was obtained from the Chemical Research Department, Schering-Plough Research Institute. HEK-293 human embryonic kidney cells stably expressing the human histamine H3 receptor were cultured in Dulbecco's modified Eagle's medium/10% fetal calf serum/peniC1llin (100 U/ml)/streptomyC1n (100 lyig/ml)/GenetiC1n (0.5 mg/ml) at 37° C in a humidified 5% CO2 atmosphere. Cells were harvested between passages five and twenty at 37° C in 5 mM EDTA/Hank's balanced salt solution and processed for membrane preparation. After low-speed centrifugation, ten min at 1000 xg, they were put into ten volumes of ice-cold buffer and disrupted with a Polytron (PTA 35/2 tip, 30 sec at setting 6). After subsequent low-speed centrifugation, supernatant was centrifuged ten min at 50,000 xg. The high-speed pellet was resuspended in the original volume of buffer, a sample was taken for protein assay (biC1nchoninic aC1d, Pierce) and the suspension was centrifuged again at 50,000 xg. Membranes were resuspended at 1 mg of protein/ml of buffer and frozen at -80° C until use. Membrane (15 pg of protein) was incubated with 1.2 nM lyHJNly-methyl-histamine, without or with inhibitor compounds, in a total volume of 200 pi of buffer. NonspeC1fic binding was determined in the presence of 10"5 M thioperamide. Assay mixtures were incubated for 30 min at 30° C in polypropylene, 96-well, deep-well plates, then filtered through 0.3% polyethylenimine-soaked GF/B filters. These were washed three times with 1.2 ml of 4° C buffer, dried in a miC1owave oven, impregnated with Meltilex wax sC1ntillant and counted at 40% effiC1ency in a Betaplate sC1ntillation counter (Wallac). IC50 values were interpolated from the data or were determined from curves fit to the data with Prism nonlinear least squares curve-fitting program (GraphPad Software, San Diego, CA). Kj values were determined from IC50 values according to the Cheng and Prusoff equation. In these assays, compounds of formula I have a Kj within the range of about 0.1 to about 600 nM. Preferred compounds of formula I have a Kj within the range of about 0.1 to about 100 nM. More preferred compounds of formula I have a Kt within the range of about 0.1 to about 20 nM. Representative compounds of the present invention tested according to the In this speC1fication, the term "at least one compound of formula r means that one to three different compounds of formula I may be used in a pharmaceutical composition or method of treatment. Preferably one compound of formula I is used. Similarly, "at least one H1 receptor antagonist * means that one to three different H1antagonists may be used in a pharmaceutical composition or method of treatment. Preferably, one H1antagonist is used. For preparing pharmaceutical compositions from the compounds desC1ibed by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), The SC1ence and Practice of Pharmacy, 20th Edition, (2000), Lippincott Williams & Wilkins, Baltimore, MD. Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opaC1fiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration-Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable earner, such as an inert compressed gas, e.g. nitrogen. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of C1eams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. Preferably the compound is administered orally. Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose. The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 350 mg, preferably from about 1 mg to about 150 mg, more preferably from about 1 mg to about 50 mg, according to the particular application. The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required. The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending cliniC1an considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day, preferably 1 mg/day to 75 mg/day, in two to four divided doses. When the invention comprises a combination of H3 antagonist and H1antagonist compounds, the two active components may be co-administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H3 antagonist and an Hly antagonist in a pharmaceutically acceptable carrier can be administered. The components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc. The dosage of the H-» antagonist can be determined from published material, and may range from 1 to 1000 mg per dose. When separate H3 and H1antagonist pharmaceutical compositions are to be administered, they can be provided in a kit comprising in a single package, one container comprising an H3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising an Hly antagonist in a pharmaceutically acceptable carrier, with the H3 and H1antagonists being present in amounts such that the combination is therapeutically effective. A kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms. While the present invention has been desC1ibed in conjunction with the speC1fic embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention. WHAT IS CLAIMED IS: or a pharmaceutically acceptable salt or solvate thereof, wherein: the dotted line represents an optional double bond; a is 0 to 2; b is 0 to 2; n is 1, 2 or 3; p is 1, 2 or 3; risO, 1,2, or 3; with the provisos that when M2 is N, p is not 1; and that when r is 0, M2 is C(R3); and that the sum of p and r is 1 to 4; M1 is C(R3) or N; M2 is C(R3) or N; X is a bond or C1-C6 alkylene; Y is -C(O)-, -C(S)-, -(CH2)q -, -NR4C(0)-, -C(0)NR4-, -C(0)CH2-, -SOr, -N(R4)-, -NH-C(=N-CN)- or-C(=N-CN)-NH-; with the provisos that when M1 is N, Y is not -NR4C(0)- or -NH-C(=N-CN)-; when M2 is N, Y is not -C(0)NR4- or -C(=N-CN)-NH-; and when Y is -N(R4)-, M1 is CH and M2 is C(R3); q is 1 to 5, provided that when both M1 and M2 are N, q is 2 to 5; Z is a bond, d-Cs alkylene, C1-C6 alkenylene, -C(O)-, -CH(CN)-, -SO2- or -CH2C(0)NR4-; R is H, C1C6 alkyl, ha!o(C1-C6)alkyl-, C1-C6 alkoxy, (C1-C6)alkoxy-1 (C1-C6)alkyl-,(C1-C6)-alkoxy-(C1-C6)alkoxy>(C1-C6)alkoxy-(C1-C6)alkyl-SOo.2, R32-aryl(C1-C6)alkoxy-> R32-aryl(d-C6)alkyl-, R32-aryl, R32-aryloxy, R32-heteroaryl, (C3-C6)cycloalkyl, (C3-C6)Jcycloalkyl-(C1-C6)Jalkyl, (C3-C6)cycloalkyl-(C1-C6)alkoxy, (C3-C6)cycloalkyl-oxy-, R37-heterocycloalkyl, R37-heterocycloalkyl-oxy-, R^-heterocycloalkyl(C1-C6)alkoxy, N(R30)(R31HC1-C6)alkyl-,-N(R30)(R31)t -NH-(d-C6)alkyl-0-(d-C6)alkyl, -NHC(0)NH(R29); R29-S(O)0.2-, halo(C1-C6)alky!-S(0)a-2-, N(R30)(R31)-(C1-C6)alkyl-S(0)o-2- or benzoyl; R8 is H, d-C6 alkyl, halo(C1-C6)alkyl-, (d-C6)alkoxy-(d-C6)alkyl-, R32-aryl(d-C6)alky!-, R32-aryl, R32-heteroaryl, (C3-C6)cycloalkyl, (C3-C6)cycloalkyl-(d-C6)alkyl, R37-heterocycloalkyl, N(R30)(R31)-(C1-C6)alkyl-, R29-S(0)2-. halo(d-C6)alkyl-S(0)2-, R29-S(0)o-r{C2-C6)alkyl-, halo(d-C6)alkyl-S(0)o-i-(C2-C6)alkyl-; R2 is a six-membered heteroaryl ring having 1 or 2 heteroatoms independently selected from N or N-O, with the remaining ring atoms being carbon; a five-membered heteroaryl ring having 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, with the remaining ring atoms being carbon; R32-quinolyl; R32-aryl; heterocycloalkyl; (C3-C6)cycloalkyl; d-C6 alkyl; hydrogen; thianaphthenyl; wherein said six-membered heteroaryl ring or said five-membered heteroaryl ring is optionally substituted by R6; R3 is H, halogen, d-G6 alky!, -OH, (C1-C6)alkoxy or-NHSOr(C1-C6)alkyl; R4 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, R33-aryl, R33-ary(C1-C6)alkyl, and R32-heteroaryl; R5 is hydrogen, C1-C6 alkyl, -C(0)R20, -C(0)2R2°, -C(O)N(R20)2, (C1-C6)alkyl-S02-, or (C1-C6)alkyl-S02-NH-; or R4 and R5, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring; R6 is 1 to 3 substituents independently selected from the group consisting of -OH, halogen, C1-C6 alkyl-, C1-C6 alkoxy, C1-C6 alkylthio, -CF3, -NR4R5, -CH2-NR4R5, -NHS02R22, -N(S02R22)2, phenyl, R33-phenyl, N02, -C02R4, -C0N(R4)2, R7 is -N(R29)-, -O- or -S(O)0.2-; R12 is independently selected from the group consisting of C1-C6 alkyl, hydroxyl, C1-C6 alkoxy, or fluoro, provided that when R12 is hydroxy or fluoro, then R12 is not bound to a carbon adjacent to a nitrogen; or two R12 substituents form a C1 to C2 alkyl bridge from one ring carbon to another non-adjacent ring carbon; or R12 is =0; R13 is independently selected from the group consisting of C1-Ce alkyl, hydroxyl, C1-C6 alkoxy, or fluoro, provided that when R13 is hydroxy or fluoro then R13 is not bound to a carbon adjacent to a nitrogen; or two R13 substituents form a C1 to C2 alkyl bridge from one ring carbon to another non-adjacent ring carbon; or R13 is =0; R20 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, or aryl, wherein said aryl group is optionally substituted with from 1 to 3 groups independently selected from halogen, -CF3, -OCF3, hydroxyl, or methoxy; or when two R20 groups are present, said two R20 groups taken together with the nitrogen to which they are bound can form a five or six membered heterocyclic ring; R22 is C1-C6 alkyl, R34-aryl or heterocycloalkyl; R24 is H, C1-C6 alkyl, -S02R22 or R34-aryl; R25 is independently selected from the group consisting of C1-C6 alkyl, halogen, -CN, -N02, -CF3, -OH, C1-C6 alkoxy, (C1-C6)alkyl-C(0)-, aryl-C(O)-, -C(0)0R29, -N(R4)(R5). N(R4)(R5)-C(Oh N(R4)(R5)-S(0)1.2-. R22-S(0)o-2-, halo-(C1-C6)alkyl- or halo^d-CeJalkoxy^C1-Celalkyl-; R29 is H, C1-C6 aikyl, C3-C6 cycloalkyl, R35-aryl or R35-aryl(C1-C6)alkyl-; R30 is H, d-C6 alkyl-, R35-aryl or R35-aryl(d-C6)alkyl-; R31 is H, C1-C6 alkyl-, R35-aryl, R35-aryl(C1-C6)alkyl-, R35-heteroaryl, (C1-C6)alkyl-C(0)-, R35-aryl-C(0)-, N(R4)(R5)-C(0)-, (C1-C8)alkyl-S or R30 and R31 together are -(CH2)4-5-, -(CH2)2-0-(CH2)2- or -(CH2)2-N(R38)-(CH2)2- and form a ring with the nitrogen to which they are attached; R32 is 1 to 3 substituents independently selected from the group consisting of H, -OH, halogen, C1-C6 alkyl, d-C6 alkoxy, R35-aryl-0-, -SR22, -CF3, -OCF3, -OCHF2, -NR39R40, phenyl, R33-phenyl, N02, -C02R39, -CON(R39)2, -S(0)2R22, -S(O)2N(R20)2, -N(R24)S(0)2R22, -CN, hydroxy-(C1-C6)alkyl-, -OCH2CH2OR22, and R35-aryl(C1-C6)alkyl-0-, or two R32 groups on adjacent carbon atoms together form a -OCH20- or -0(CH2)zO- group; R33 is 1 to 3 substituents independently selected from the group consisting of C1-C6 alkyl, halogen, -CN, -N02, -CF3l -OCF3, -OCHF2 and -0-(C1-C6)alkyl; R34 is 1 to 3 substituents independently selected from the group consisting of H, halogen, -CF3. -OCF3, -OH and -OCH3; R35 is 1 to 3 substituents independently selected from hydrogen, halo, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, phenoxy, -CF3, -N(R36)2, -COOR20 and -N02; R36 is independently selected form the group consisting of H and d-C6 alkyl; R37 is 1 to 3 substituents independently selected from hydrogen, halo, C1-C6 alkyl, hydroxy, C1-C6 alkoxy, phenoxy, -CF3, -N(R36)2> -COOR20, -C(0)N(R29)2 and -N02, or R37 is one or two =0 groups; R38 is H, C1-C6 alkyl, R35-aryl, R35-aryl(C1-C6)alkyl-, (C1-C6)alkyl-S02 or ' halo(C1-C6)alkyl-S02-; R39 is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C6)cycloalkyl(C1-C6)alkyl, R33-aryl, R33-aryl(C1-C6)alkyl, and R32-heteroaryl; and R40 is hydrogen, C1-C6 alkyl, -C(0)R20, -C(0)2R20. -C(O)N(R20)2, (C1-C6)alkyl-SOr. or (d-CeJalkyl-SOrNH-; or R39 and R40, together with the nitrogen to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring. 2. A compound of claim 1 wherein M1 is N, a is 0, and n is 2, and the optional double bond is not present. 3. A compound of claim 2 wherein M2 is C(R3) wherein R3 is hydrogen or fluorine, b is 0, ris 1, and p is 2. 4. A compound of claim 3 wherein X is a bond. 5. A compound of claim 4 wherein Y is -C(O)-. 6. A compound of claim 5 wherein Z is straight or branched C1-C3 alkyl. 7. A compound of claim 6 wherein R2 is a six-membered heteroaryl ring, optionally substituted with one R6 substituent. 8. A compound of claim 7 wherein R2 is pyrimidy, R^pyrimidyl, pyridyl, R^pyridyl or pyridazinyl and R6 is -NH2. 9. A compound of claim 8 wherein R2 is 10. A compound of claim 2 wherein R1 is 11. A compound of claim 10 wherein R is (d-C6)alkylr (d-C6)alkoxy, (C1- C6)alkoxy(C1-C6)alkoxy, (C1-C6)alkylthio, heteroaryl or R32-aryl; R25 is halogen or- CF3; and k and k1 are 0 or 1. 12. A compound of claim 11 wherein R is -CH3, -CH2CH3, -OCH3t -OCH2CH3, - QCH2CH2CH3, -OCH((CH3)2, -CH2CH3, -SCH3, -SCH2CH3l pyridyl, pyrimidyl, pyrazinyl, furanyl, oxazolyl or R32-phenyl. 15. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceuticallyeffective carrier. 16. The use of a compound of claim 1 for the preparation of a medicament for treating allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and aC1dic seC1-etion of the gastro-intestinal tract, obesity, sleeping disorders, disturbances of the central nervous system, attention defiC1t hyperactivity disorder, hypo and hyperactivity of the central nervous system, Alzheimer's disease, schizophrenia, and migraine. 17. A pharmaceutical composition comprising an effective amount of a compound of claim 1, and an effective amount of H1 receptor antagonist, and a pharmaceuticallyeffective carrier. 18. The use of a compound of claim 1 for the preparation of a medicament for use in combination with an H1 receptor antagonist for treating allergy, allergy-induced airway responses, and congestion. 19. The use of claim 19 wherein said H1 receptor antagonist is selected from: astemizole, azatadine, azelastine, aC1-ivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine or triprolidine. 20. A compound represented by the structural formula substantially as herein desC1-ibed and exemplified.

Documents:

2313-CHENP-2004 ABSTRACT.pdf

2313-CHENP-2004 CLAIMS GRANTED.pdf

2313-CHENP-2004 CORRESPONDENCE OTHERS.pdf

2313-CHENP-2004 CORRESPONDENCE PO.pdf

2313-CHENP-2004 FORM 2.pdf

2313-CHENP-2004 FORM 3.pdf

2313-CHENP-2004 PETITION.pdf

2313-CHENP-2004 POWER OF ATTORNEY.pdf

2313-chenp-2004-claims.pdf

2313-chenp-2004-correspondnece-others.pdf

2313-chenp-2004-correspondnece-po.pdf

2313-chenp-2004-description(complete).pdf

2313-chenp-2004-form 1.pdf

2313-chenp-2004-form 3.pdf

2313-chenp-2004-form 5.pdf

2313-chenp-2004-form18.pdf

2313-chenp-2004-pct.pdf

abs-2313.jpg